Utah Business Magazine Recognizes Recursion’s Tina Larson, Civica’s Heather Wall Among Utah’s Top C-Suite Executives

Recursion’s President and Chief Operating Officer, Tina Larson, and Civica’s Chief Commercial Officer, Heather Wall, were recently recognized by Utah Business Magazine as among Utah’s top C-Suite executives. In introducing the 2020 CXO of the Year honorees, the magazine notes that “now more than ever we need strong leaders to guide our businesses forward and […]

Read More

Foldax Named Finalist in the Fierce Innovation Awards

Salt Lake City-based Foldax® was a finalist in the recent Fierce Innovation Awards – Life Sciences Edition 2020, a peer-reviewed awards program from the publisher of Fierce Biotech and Fierce Pharma. The company was selected as a finalist for its innovative TriaTM heart valve. The Tria valve reimagines the heart valve by incorporating a new, […]

Read More

Alucent Biomedical Announces $35 Million Series B Financing

Alucent Biomedical, a Salt Lake-City based company and BioUtah member, founded to transform the way vascular disease is treated, yesterday announced the close of a $35 million Series B financing round. The funding will support two clinical trials to evaluate Alucent’s novel treatment for peripheral artery disease (PAD) of the lower extremities. PAD is a […]

Read More

IONIQ Sciences’ ProLung Test Accepted for Submission to China’s National Medical Products Administration

IONIQ Sciences, based in Salt Lake City, and a BioUtah member, announced September 20 that its IONIQ ProLung Test™ for lung cancer has been formally accepted for submission to China’s National Medical Products Administration (NMPA), formerly known as the Chinese Food and Drug Administration (CFDA).  Mr. Jared Bauer, IONIQ Sciences CEO, stated, “We are excited […]

Read More

SDP Oncology Announces New Data from Phase 1 Solid Tumor Study

Lehi-based Sumitomo Dainippon Pharma Oncology (SDP Oncology) and BioUtah member recently announced new data from the ongoing Phase 1 study evaluating dubermatinib (TP-0903) in patients with advanced solid tumors.  “These preliminary data presented at ESMO 2020 are encouraging as we learn more about how dubermatinib may inhibit the AXL kinase protein and sensitize cancer cells […]

Read More

The Point Kick Off

On Monday, government leaders, including Lt. Governor Spencer Cox, held a press conference announcing the launch of planning efforts to redevelop the site of the Utah State Prison (The Point) in Draper. Many of our industry leaders are participating on The Point’s Education, Research and Innovation working group – Randy Rasmussen (former BioFire CEO), Gary […]

Read More

RenalytixAI Reaches Milestone of KidneyIntelX Commercial Testing with Mount Sinai Health System

Salt Lake City-based RenalytixAI, today announced the commercial launch of the KidneyIntelX clinical test reporting platform within the Mount Sinai Health System. This means that KidneyIntelX risk assessment of progressive decline in kidney function or kidney failure, including education support for treating clinicians, is now commercially available for patients with early stage diabetic kidney disease […]

Read More

Clene Nanomedicine, Inc. Completes Enrollment in Rescue-ALS Clinical Trial for Treatment of Amyotrophic Lateral Sclerosis (ALS) with Lead Nanocatalytic Therapeutic, CNM-Au8

Clene Nanomedicine, Inc., (“Clene”) a clinical-stage biopharmaceutical company and its Australian subsidiary, Clene Australia Pty Ltd., on Tuesday announced the completion of patient enrollment in its RESCUE-ALS Phase 2 study. The multi-center study is designed to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of CNM-Au8 in early symptomatic ALS patients. The objective of this study […]

Read More

Inherent Biosciences Wins $256K NSF Grant to predict COVID-19 infection severity and treatment response

Inherent Biosciences, a biotechnology company headquartered in Salt Lake City has announced a $255,959 award from the National Science Foundation (NSF) to study epigenetic biomarkers to predict patient response to COVID-19. The SBIR Phase I project aims to develop an onsite, clinical test to screen incoming patients potentially infected with COVID-19. The test would predict […]

Read More

BioUtah Statement on Launch of Altitude Lab, Largest Life Sciences Incubator in Utah

Posted on

Recursion and University of Utah found incubator to propel new generation of life sciences in the region August 12, 2020 04:18 PM Eastern Daylight Time SALT LAKE CITY–(BUSINESS WIRE)–BioUtah President and CEO, Kelvyn Cullimore, issued the following statement following the announcement of the opening of Altitude Lab. “This is truly a life sciences milestone in […]

Read More